期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
光化学治疗系统性硬化症的一项随机、双盲、安慰剂对照临床试验
1
作者 Knobler R.M. French L.E. +1 位作者 kim y. 朱国兴 《世界核心医学期刊文摘(皮肤病学分册)》 2006年第8期42-42,共1页
Background: Systemic sclerosis is a multisystemic connective tissue disease with marked involvement of the skin and joints for which few effective evidence based therapies are available. To further investigate the eff... Background: Systemic sclerosis is a multisystemic connective tissue disease with marked involvement of the skin and joints for which few effective evidence based therapies are available. To further investigate the efficacy of extracorporeal photochemotherapy on early aggresive cutaneous disease, a randomized, double-blind, placebo-controlled trial was performed. Objective: Our aim was to evaluate the efficacy of photopheresis in the treatment of patients with systemic sclerosis (scleroderma). Methods: This randomized, double-blind, placebo-controlled clinical trial was conducted at 16 investigational sites in the United States, Canada, and Europe. Sixty-four patients with typical clinical and histologic findings of scleroderma, of less than 2 years’ duration, were studied. Patients did not receive any other concomitant treatment for scleroderma. Patients were randomized to receive either active or sham photopheresis treatment on two consecutive days monthly for 12 months. Severity of skin (skin scores assessed in 22 body regions) and joint involvement (60 joints examined for contractures) were assessed on a monthly basis. Results: A statistically significant improvement in skin scores as compared with baseline was observed at 6 months (P = .0024) and 12 months (P = .008) among those who received active photopheresis, but not among those who received sham photopheresis. Comparison of skin scores between the two study arms did not achieve statistical significance because of the small sample size of the study arms. Joint involvement was also significantly improved after 6 months (P = .002) and 12 months (P = .001) of active photopheresis when compared with baseline. Limitations: The study lacks sufficient statistical power to reveal a significant difference in skin and joint manifestations between the active and sham photopheresis arms. Conclusion: Photopheresis induced significant improvement of skin and joint involvement in patients with scleroderma of recent onset; however, any effect when compared with sham treatment and a possible placebo effect may be modest. 展开更多
关键词 对照临床试验 系统性硬化症 光化学治疗 随机分组 安慰剂 双盲 体外光化学疗法 统计学差异 患者皮肤 关节受累
下载PDF
原发性皮肤大B细胞淋巴瘤患者中与疾病特异性存活时间相关的bcl-6和MUM1/IRF4蛋白的表达:组织芯片研究
2
作者 Sundram U. kim y. +1 位作者 Mraz-Gernhard S. 李政霄 《世界核心医学期刊文摘(皮肤病学分册)》 2005年第6期33-34,共2页
Background: Systemic B-cell lymphomas have been studied using microarrays, which has led to a better understanding of their molecular characteristics. Initial microarray studies of these lymphomas have implicated seve... Background: Systemic B-cell lymphomas have been studied using microarrays, which has led to a better understanding of their molecular characteristics. Initial microarray studies of these lymphomas have implicated several genes as important predictors of outcome. In this study, we used a tissue micro-array (TMA) to characterize primary cutaneous large B-cell lymphomas (PCLBCL). Methods: We studied 14 patients for whom clinical follow up was available, including four patients whose lesions were limited to the leg on presentation. Immunohistochemical staining with CD20, CD44, CD21, CD5, CD10, bcl-2, bcl-6, Ki67, p53, and multiple myeloma 1 (MUM1) was examined. Results: Our results identify two subgroups of lymphomas. The first group showed staining with bcl-6 and had an overall survival of 176 months (P=0.003). The majority of this group was negative for MUM1. The second group lacked staining with bcl-6 and had an overall survival of 26 months, with a majority of these cases staining with MUM1. Three of four patients with PCLBCL of the leg showed no staining with bcl-6. Conclusions: Our study demonstrates the utility of TMAs in the analysis of PCLBCL and that expression of bcl-6 and MUM1 correlates with survival. 展开更多
关键词 淋巴瘤患者 B细胞淋巴瘤 MUM1/IRF4 BCL-6 组织芯片 疾病特异性 存活时间 多发性骨髓瘤 生存时间 分子学
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部